Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
OBJECTIVE
We compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD.


METHODS
This analysis compared 200 patients with DSM-IV-defined schizophrenia and TD and 997 patients without TD, all of whom were randomly assigned to receive one of 4 second-generation antipsychotics. The primary clinical outcome measure was time to all-cause treatment discontinuation, and the primary measure for evaluating the course of TD was change from baseline in Abnormal Involuntary Movement Scale (AIMS) score. Kaplan-Meier survival analysis and Cox proportional hazards regression models were used to compare treatment discontinuation between groups. Changes in Positive and Negative Syndrome Scale (PANSS) and neurocognitive scores were compared using mixed models and analysis of variance. Treatment differences between drugs in AIMS scores and all-cause discontinuation were examined for those with TD at baseline. Percentages of patients meeting criteria for TD postbaseline or showing changes in AIMS scores were evaluated with χ(2) tests. Data were collected from January 2001 to December 2004.


RESULTS
Time to treatment discontinuation for any cause was not significantly different between the TD and non-TD groups (χ(2)(1) = 0.11, P = .743). Changes in PANSS scores were not significantly different (F(1,974) = 0.82, P = .366), but patients with TD showed less improvement in neurocognitive scores (F(1,359) = 6.53, P = .011). Among patients with TD, there were no significant differences between drugs in the decline in AIMS scores (F(3,151) = 0.32, P = .811); 55% met criteria for TD at 2 consecutive visits postbaseline, 76% met criteria for TD at some or all postbaseline visits, 24% did not meet criteria for TD at any subsequent visit, 32% showed a ≥ 50% decrease in AIMS score, and 7% showed a ≥ 50% increase in AIMS score.


CONCLUSIONS
Schizophrenia patients with and without TD were similar in time to discontinuation of treatment for any cause and improvement in psychopathology, but differed in neurocognitive response. There were no significant differences between treatments in the course of TD, with most patients showing either persistence of or fluctuation in observable symptoms.


BACKGROUND
clinicaltrials.gov Identifier: NCT00014001.
Caroff
Stanley N
SN
Department of Psychiatry, Veterans Affairs Medical Center and University of Pennsylvania School of Medicine, Philadelphia, USA. caroff@va.gov
Davis
Vicki G
VG
Miller
Del D
DD
Davis
Sonia M
SM
Rosenheck
Robert A
RA
McEvoy
Joseph P
JP
Campbell
E Cabrina
EC
Saltz
Bruce L
BL
Riggio
Silvana
S
Chakos
Miranda H
MH
Swartz
Marvin S
MS
Keefe
Richard S E
RS
Stroup
T Scott
TS
Lieberman
Jeffrey A
JA
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D016009:Chi-Square Distribution; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000209:etiology*; D000077152:Olanzapine; D010546:Perphenazine / Q000009:adverse effects / Q000627:therapeutic use; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D016016:Proportional Hazards Models; D011569:Psychiatric Status Rating Scales; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D012720:Severity of Illness Index; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D010546:Perphenazine; D018967:Risperidone; D000077152:Olanzapine
N Engl J Med. 2005 Sep 22;353(12):1209-23
16172203
Schizophr Bull. 1985;11(3):471-86
2863873
Br J Psychiatry. 1991 Apr;158:503-10
1675900
Int Clin Psychopharmacol. 2006 Jan;21(1):35-42
16317315
Br J Psychiatry. 1983 Oct;143:423-4
6626865
J Psychopharmacol. 2009 Jun;23(4):436-41
18583442
Mov Disord. 2006 May;21(5):589-98
16532448
Psychol Med. 1983 Feb;13(1):71-81
6133298
Br J Psychiatry. 2008 Oct;193(4):279-88
18827289
Am J Psychiatry. 1994 Jun;151(6):836-41
7910437
J Clin Psychiatry. 1993 Apr;54(4):133-9
8098030
J Clin Psychiatry. 1994 Sep;55 Suppl B:102-6
7961550
Arch Gen Psychiatry. 2007 Jun;64(6):633-47
17548746
Neuropsychopharmacology. 2006 Sep;31(9):2033-46
16641947
Am J Psychiatry. 2004 Mar;161(3):414-25
14992963
Psychopharmacol Bull. 1988;24(3):471-5
3153511
Br J Psychiatry. 1991 Jun;158:822-8
1678663
Br J Psychiatry. 2007 Sep;191:238-45
17766765
Am J Psychiatry. 2009 Sep;166(9):1055-62
19570929
J Clin Psychiatry. 2005 Sep;66(9):1130-3
16187770
J Clin Psychiatry. 2008 Oct;69(10):1580-8
19192441
J Clin Psychopharmacol. 1988 Aug;8(4 Suppl):21S-26S
3220967
Neurology. 2001 Mar 27;56(6):805-7
11274325
Acta Psychiatr Scand. 1992 Apr;85(4):295-305
1375801
Neuropsychopharmacology. 1994 Oct;11(2):107-18
7840862
Psychopharmacology (Berl). 1978 Jan 31;56(1):75-80
415329
Acta Psychiatr Scand Suppl. 1970;212:11-9
4917967
Schizophr Res. 2005 Dec 1;80(1):33-43
16171976
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Sep;28(6):985-96
15380859
Psychopharmacol Bull. 1986;22(1):254-8
2873613
Am J Psychiatry. 1971 Sep;128(3):317-23
5570997
Schizophr Bull. 1987;13(2):261-76
3616518
Br J Psychiatry. 2002 Nov;181:422-7
12411269
J Clin Psychiatry. 2004 May;65(5):696-701
15163258
J Clin Psychiatry. 2002 Jun;63(6):516-23
12088164
J Clin Psychopharmacol. 2009 Feb;29(1):5-8
19142099
Br J Psychiatry. 1989 May;154:672-6
2574607
Neuropsychopharmacology. 1996 Feb;14(2):111-23
8822534
Arch Gen Psychiatry. 1982 Apr;39(4):486-7
6121550
J Clin Psychiatry. 1998 Sep;59(9):472-7
9771818
JAMA. 2003 Nov 26;290(20):2693-702
14645311
Schizophr Bull. 1997;23(4):583-609
9365997
J Clin Psychopharmacol. 1995 Feb;15(1 Suppl 1):36S-44S
7537286
Schizophr Res. 2008 Mar;100(1-3):97-107
18055180
Schizophr Res. 2009 Aug;113(1):12-8
19545976
Am J Psychiatry. 2007 Mar;164(3):415-27
17329466
Compr Psychiatry. 2007 Sep-Oct;48(5):436-40
17707251
Arch Gen Psychiatry. 1982 Jul;39(7):803-16
6131655
Neuropsychopharmacology. 1993 May;8(3):233-9
8099483